The concept of combining METTL1 inhibitors with ICIs may hold promise in specific contexts (e.g., ICC or HCC), but its efficacy is likely to depend on the cancer type, tumor microenvironment, and immune landscape. The gene discussed is METTL1; the disease is hepatocellular carcinoma.